<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZETIA - ezetimibe tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ZETIA safely and effectively. See full prescribing information for ZETIA.
 
ZETIA (ezetimibe) Tablets
Initial U.S. Approval: 2002 </div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ZETIA<span class="Sup">®</span> is an inhibitor of intestinal 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (and related phytosterol) absorption indicated as an adjunct to diet 
to: </p>
<ul>
<li>Reduce elevated total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span> in patients with primary 
<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, alone or in combination with an HMG-CoA reductase inhibitor 
(statin) (<a href="#S1.1">1.1</a>)</li>
<li>Reduce elevated total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and non-HDL-C in patients with mixed 
<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> in combination with fenofibrate (<a href="#S1.1">1.1</a>)</li>
<li>Reduce elevated total-C and LDL-C in patients with homozygous familial 
<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (HoFH), in combination with atorvastatin or simvastatin (<a href="#S1.2">1.2</a>)</li>
<li>Reduce elevated sitosterol and campesterol in patients with homozygous 
sitosterolemia (phytosterolemia) (<a href="#S1.3">1.3</a>)</li>
</ul>
<p class="Highlighta">Limitations of Use (<a href="#S1.4">1.4</a>) </p>
<ul>
<li>The effect of ZETIA on cardiovascular morbidity and mortality has not been 
determined.</li>
<li>ZETIA has not been studied in Fredrickson Type I, III, IV, and V 
<span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>.</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>One 10-mg tablet once daily, with or without food (<a href="#S2.1">2.1</a>)</li>
<li>Dosing of ZETIA should occur either ≥2 hours before or ≥4 hours after 
administration of a bile acid sequestrant. (<a href="#S2.3">2.3</a>, <a href="#S7.4">7.4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Tablets: 10 mg (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Statin contraindications apply when ZETIA is used with a statin: 
<ul>
<li>Active liver disease, which may include unexplained persistent elevations in 
hepatic transaminase levels (<a href="#S4">4</a>, <a href="#S5.2">5.2</a>)</li>
<li>Women who are pregnant or may become pregnant (<a href="#S4">4</a>, <a href="#S8.1">8.1</a>)</li>
<li>Nursing mothers (<a href="#S4">4</a>, <a href="#S8.3">8.3</a>)</li>
</ul>
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to product components (<a href="#S4">4</a>, <a href="#S6.2">6.2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>ZETIA is not recommended in patients with moderate or severe hepatic 
impairment. (<a href="#S5.4">5.4</a>, <a href="#S8.6">8.6</a>, <a href="#S12.3">12.3</a>)</li>
<li>Liver enzyme abnormalities and monitoring: Persistent elevations in hepatic 
transaminase can occur when ZETIA is added to a statin. Therefore, when ZETIA is 
added to statin therapy, monitor hepatic transaminase levels before and during 
treatment according to the recommendations for the individual statin used. (<a href="#S5.2">5.2</a>)</li>
<li>Skeletal muscle effects (e.g., <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>): 
<ul><li>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients treated 
with ZETIA co-administered with a statin and with ZETIA administered alone. Risk 
for skeletal muscle toxicity increases with higher doses of statin, advanced age 
(&gt;65), <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and depending on the statin used, 
concomitant use of other drugs. (<a href="#S5.3">5.3</a>, <a href="#S6.2">6.2</a>)</li></ul>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><ul><li>Common adverse reactions in clinical trials: 
<ul><li>ZETIA co-administered with a statin (incidence ≥2% and greater than statin 
alone): 
<ul><li><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and 
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (<a href="#S6">6</a>)</li></ul>
</li></ul>
<ul><li>ZETIA administered alone (incidence ≥2% and greater than placebo): 
<ul><li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> 
in extremity (<a href="#S6">6</a>)</li></ul>
</li></ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact 
Merck/Schering-Plough Pharmaceuticals at 1-866-637-2501 or FDA at 1-800-FDA-1088 
or www.fda.gov/medwatch.</span> </p>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<ul>
<li>Cyclosporine: Combination increases exposure of ZETIA and cyclosporine. 
Cyclosporine concentrations should be monitored in patients taking ZETIA 
concomitantly. (<a href="#S7.1">7.1</a>, <a href="#S12.3">12.3</a>)</li>
<li>Fenofibrate: Combination increases exposure of ZETIA. If <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span> is 
suspected in a patient receiving ZETIA and fenofibrate, gallbladder studies are 
indicated and alternative lipid-lowering therapy should be considered. (<a href="#S6.1">6.1</a>, <a href="#S7.3">7.3</a>)</li>
<li>Fibrates: Co-administration of ZETIA with fibrates other than fenofibrate is 
not recommended until use in patients is adequately studied. (<a href="#S7.2">7.2</a>)</li>
<li>Cholestyramine: Combination decreases exposure of ZETIA. (<a href="#S2.3">2.3</a>, <a href="#S7.4">7.4</a>, <a href="#S12.3">12.3</a>)</li>
</ul>
<br>
</div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h1><a href="#section-13" class="toc">13  NON CLINICAL TOXICOLOGY</a></h1>
<h1><a href="#section-14" class="toc">14  CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2  Liver Enzymes</a></h2>
<h2><a href="#section-16.3" class="toc">17.3  Pregnancy</a></h2>
<h2><a href="#section-16.4" class="toc">17.4  Breastfeeding</a></h2>
<h2><a href="#section-16.5" class="toc">17.5  FDA-approved Patient Labeling</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Z1"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">Therapy with lipid-altering agents should be only one component 
of multiple risk factor intervention in individuals at significantly increased 
risk for atherosclerotic vascular disease due to <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. Drug 
therapy is indicated as an adjunct to diet when the response to a diet 
restricted in saturated fat and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and other nonpharmacologic measures 
alone has been inadequate.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>1.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span><a href="http://"></a><p><span class="Italics">Monotherapy</span></p>
<p>ZETIA<a href="#footnote-1">1</a>, 
administered alone, is indicated as adjunctive therapy to diet for the reduction 
of elevated total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (total-C), low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> 
(LDL-C), and <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (<span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>) in patients with primary (heterozygous 
familial and non-familial) <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. </p>
<a href="#footnote-reference-1">1</a>COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough 
Pharmaceuticals.<br>All rights reserved. <a href="http://"></a><p><span class="Italics">Combination Therapy with HMG-CoA Reductase 
Inhibitors (Statins)</span></p>
<p>ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme 
A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to 
diet for the reduction of elevated total-C, LDL-C, and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span> in patients with 
primary (heterozygous familial and non-familial) <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>.</p>
<a href="http://"></a><p><span class="Italics">Combination Therapy with Fenofibrate</span></p>
<p>ZETIA, administered in combination with fenofibrate, is indicated as 
adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, 
and non-high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (non-HDL-C) in adult patients with 
mixed <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>1.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> 
(HoFH)<p>The combination of ZETIA and atorvastatin or simvastatin is 
indicated for the reduction of elevated total-C and LDL-C levels in patients 
with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL 
apheresis) or if such treatments are unavailable.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>1.3 Homozygous Sitosterolemia<p>ZETIA is indicated as adjunctive therapy to diet for the 
reduction of elevated sitosterol and campesterol levels in patients with 
homozygous familial sitosterolemia. </p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>1.4 Limitations of Use<p>The effect of ZETIA on cardiovascular morbidity and mortality has 
not been determined.</p>
<p>ZETIA has not been studied in Fredrickson Type I, III, IV, and V 
<span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Z2"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<a href="http://"></a>2.1 General Dosing Information<p class="First">The recommended dose of ZETIA is 10 mg once daily. </p>
<p>ZETIA can be administered with or without food.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>2.2 Concomitant Lipid-Lowering Therapy<p>ZETIA may be administered with a statin (in patients with primary 
<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>) or with fenofibrate (in patients with mixed <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>) for 
incremental effect. For convenience, the daily dose of ZETIA may be taken at the 
same time as the statin or fenofibrate, according to the dosing recommendations 
for the respective medications.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>2.3 Co-Administration with Bile Acid 
Sequestrants<p>Dosing of ZETIA should occur either ≥2 hours before or ≥4 hours 
after administration of a bile acid sequestrant <span class="Italics">[see <a href="#S7.4">Drug Interactions (7.4)</a>]</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>2.4 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span><p>No dosage adjustment is necessary in patients with mild hepatic 
impairment <span class="Italics">[see <a href="#S5.4">Warnings and Precautions 
(5.4)</a>]</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>2.5 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><p>No dosage adjustment is necessary in patients with renal 
impairment <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology 
(12.3)</a>].</span></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>2.6 Geriatric Patients<p>No dosage adjustment is necessary in geriatric patients <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Z3"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">10-mg tablets are white to off-white, capsule-shaped tablets debossed with "414" 
on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Z4"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">ZETIA is contraindicated in the following conditions:</p>
<ul>
<li>The combination of ZETIA with a statin is contraindicated in patients with 
active liver disease or unexplained persistent elevations in hepatic 
transaminase levels.</li>
<li>Women who are pregnant or may become pregnant. Because statins decrease 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and possibly the synthesis of other biologically active 
substances derived from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, ZETIA in combination with a statin may 
cause fetal harm when administered to pregnant women. Additionally, there is no 
apparent benefit to therapy during pregnancy, and safety in pregnant women has 
not been established. If the patient becomes pregnant while taking this drug, 
the patient should be apprised of the potential hazard to the fetus and the lack 
of known clinical benefit with continued use during pregnancy. <span class="Italics">[See <a href="#S8.1">Use in Specific Populations 
(8.1)</a>.]</span>
</li>
<li>Nursing mothers. Because statins may pass into breast milk, and because 
statins have the potential to cause serious adverse reactions in nursing 
infants, women who require ZETIA treatment in combination with a statin should 
be advised not to nurse their infants<span class="Italics"> [see <a href="#S8.3">Use in Specific Populations (8.3)</a>].</span>
</li>
<li>Patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product. 
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> 
have been reported with ZETIA <span class="Italics">[see <a href="#S6.2">Adverse 
Reactions (6.2)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Z5"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<a href="http://"></a>5.1 Use with Statins or Fenofibrate<p class="First">Concurrent administration of ZETIA with a specific statin or 
fenofibrate should be in accordance with the product labeling for that 
medication.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>5.2 Liver Enzymes<p>In controlled clinical monotherapy studies, the incidence of 
consecutive elevations (≥3 × the upper limit of normal [ULN]) in hepatic 
transaminase levels was similar between ZETIA (0.5%) and placebo (0.3%).</p>
<p>In controlled clinical combination studies of ZETIA initiated concurrently 
with a statin, the incidence of consecutive elevations (≥3 × ULN) in hepatic 
transaminase levels was 1.3% for patients treated with ZETIA administered with 
statins and 0.4% for patients treated with statins alone. These elevations in 
transaminases were generally asymptomatic, not associated with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, and 
returned to baseline after discontinuation of therapy or with continued 
treatment. When ZETIA is co-administered with a statin, liver tests should be 
performed at initiation of therapy and according to the recommendations of the 
statin. Should an increase in ALT or AST ≥3 × ULN persist, consider withdrawal 
of ZETIA and/or the statin.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>5.3 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span><p>In clinical trials, there was no excess of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> or 
<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> associated with ZETIA compared with the relevant control arm 
(placebo or statin alone). However, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> are known 
adverse reactions to statins and other lipid-lowering drugs. In clinical trials, 
the incidence of creatine phosphokinase (CPK) &gt;10 × ULN was 0.2% for ZETIA vs 
0.1% for placebo, and 0.1% for ZETIA co-administered with a statin vs 0.4% for 
statins alone. Risk for skeletal muscle toxicity increases with higher doses of 
statin, advanced age (&gt;65), <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and depending 
on the statin used, concomitant use of other drugs.</p>
<p>In post-marketing experience with ZETIA, cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> 
have been reported. Most patients who developed <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> were taking a 
statin prior to initiating ZETIA. However, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> has been reported with 
ZETIA monotherapy and with the addition of ZETIA to agents known to be 
associated with increased risk of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, such as fibrates. ZETIA and 
any statin or fibrate that the patient is taking concomitantly should be 
immediately discontinued if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. The presence of 
muscle symptoms and a CPK level &gt;10 × the ULN indicates <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>5.4 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span><p>Due to the unknown effects of the increased exposure to ezetimibe 
in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, ZETIA is not recommended 
in these patients. <span class="Italics">[See <a href="#S12.3">Clinical 
Pharmacology (12.3)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Z6"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater 
detail in other sections of the label:</p>
<ul>
<li>Liver enzyme abnormalities <span class="Italics">[see <a href="#section-"> Warnings 
and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> and <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see <a href="#section-"> Warnings and Precautions (5.3)</a>]</span>
</li>
</ul>
<a href="#section-"></a><p><span class="Underline">Monotherapy Studies:</span> In the ZETIA 
controlled clinical trials database (placebo-controlled) of 2396 patients with a 
median treatment duration of 12 weeks (range 0 to 39 weeks), 3.3% of patients on 
ZETIA and 2.9% of patients on placebo discontinued due to adverse reactions. The 
most common adverse reactions in the group of patients treated with ZETIA that 
led to treatment discontinuation and occurred at a rate greater than placebo 
were:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> (0.3%)</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (0.2%)</li>
<li>Gamma-glutamyltransferase increased (0.2%)</li>
</ul>
<p>The most commonly reported adverse reactions (incidence ≥2% and greater than 
placebo) in the ZETIA monotherapy controlled clinical trial database of 2396 
patients were: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> (4.3%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (4.1%), 
<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (3.0%), <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> (2.8%), and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span> (2.7%).</p>
<a href="#section-"></a><p><span class="Underline">Statin Co-Administration Studies: </span>In 
the ZETIA + statin controlled clinical trials database of 11,308 patients with a 
median treatment duration of 8 weeks (range 0 to 112 weeks), 4.0% of patients on 
ZETIA + statin and 3.3% of patients on statin alone discontinued due to adverse 
reactions. The most common adverse reactions in the group of patients treated 
with ZETIA + statin that led to treatment discontinuation and occurred at a rate 
greater than statin alone were:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased (0.6%)</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> (0.5%)</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in 
extremity (each at 0.2%)</li>
</ul>
<p>The most commonly reported adverse reactions (incidence ≥2% and greater than 
statin alone) in the ZETIA + statin controlled clinical trial database of 11,308 
patients were: <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (3.7%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (3.2%), upper respiratory tract 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (2.9%), <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (2.6%) and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.5%). </p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>6.1 Clinical Trials Experience<p>Because clinical studies are conducted under widely varying 
conditions, adverse reaction rates observed in the clinical studies of a drug 
cannot be directly compared to rates in the clinical studies of another drug and 
may not reflect the rates observed in clinical practice.</p>
<a href="#section-"></a><p><span class="Italics">Monotherapy</span></p>
<p>In 10 double-blind, placebo-controlled clinical trials, 2396 patients with 
primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (age range 9–86 years, 50% women, 90% Caucasians, 5% 
Blacks, 3% Hispanics, 2% Asians) and elevated LDL-C were treated with ZETIA 10 
mg/day for a median treatment duration of 12 weeks (range 0 to 39 weeks).</p>
<p>Adverse reactions reported in ≥2% of patients treated with ZETIA and at an 
incidence greater than placebo in placebo-contr<span>olled studies of 
ZETIA, regardless of causality assessment, are shown in <span class="Bold">Table 
1</span>.</span></p>
<a href="#section-"></a><a name="i2a889505-0d37-4498-87c1-f8d8c725e571"></a><table width="80%">
<caption><span>TABLE 1: Clinical Adverse Reactions Occurring in ≥2% of Patients 
Treated with ZETIA and at an Incidence Greater than Placebo, Regardless of 
Causality</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<tbody class="Headless">
<tr class="First">
<td align="left">Body System/Organ Class<br>  Adverse Reaction</td>
<td align="center">ZETIA 10 mg <br>(%)<br>n = 2396</td>
<td align="center">Placebo<br>(%)<br>n = 1159</td>
</tr>
<tr>
<td align="left"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td align="center"><br></td>
<td align="center"><br></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">4.1</td>
<td align="center">3.7</td>
</tr>
<tr><td align="left"><span class="Italics">General disorders and 
administration site conditions</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">2.4</td>
<td align="center">1.5</td>
</tr>
<tr><td align="left"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and 
<span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td align="center">2.0</td>
<td align="center">1.5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center">2.8</td>
<td align="center">2.2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="center">4.3</td>
<td align="center">2.5</td>
</tr>
<tr><td align="left"><span class="Italics">Musculoskeletal and connective 
tissue disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center">3.0</td>
<td align="center">2.2</td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td align="center">2.7</td>
<td align="center">2.5</td>
</tr>
</tbody>
</table>
<p>The frequency of less common adverse reactions was comparable between ZETIA 
and placebo.</p>
<a href="#section-"></a><p><span class="Italics">Combination with a Statin</span></p>
<p>In 28 double-blind, controlled (placebo- or active-controlled) clinical 
trials, 11,308 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (age range 10–93 years, 48% 
women, 85% Caucasians, 7% Blacks, 4% Hispanics, 3% Asians) and elevated LDL-C 
were treated with ZETIA 10 mg/day concurrently with or added to on-going statin 
therapy for a median treatment duration of 8 weeks (range 0 to 112 weeks).</p>
<p>The incidence of consecutive increased transaminases (≥3 × ULN) was higher in 
patients receiving ZETIA administered with statins (1.3%) than in patients 
treated with statins alone (0.4%). <span class="Italics">[See <a href="#section-"> Warnings and Precautions (5.2)</a>.]</span></p>
<p>Clinical adverse reactions reported in ≥2% of patients treated with ZETIA + 
statin and at an incidence greater than statin, regardless of causality 
assessment, are shown in <span class="Bold">Table 2</span>.</p>
<p><span class="Bold">TABLE 2: Clinical Adverse Reactions Occurring in ≥2% of Patients Treated with 
ZETIA <br>                        Co-Administered with a Statin and at an Incidence Greater than Statin, 
<br>                                                               Regardless of Causality</span></p>
<a name="ia0300c52-69e3-472e-8112-036dfcc0cc05"></a><table width="80%"><tbody class="Headless">
<tr class="First">
<td>Body System/Organ Class<br>  Adverse Reaction</td>
<td>All Statins *<a href="#section-"></a><br>(%)<br>n = 9361</td>
<td>ZETIA + All Statins *<br>(%)<br>n = 11,308</td>
</tr>
<tr><td><span class="Italics">Gastrointestinal 
disorders</span></td></tr>
<tr>
<td>  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td>2.2</td>
<td>2.5</td>
</tr>
<tr><td><span class="Italics">General disorders and 
administration site conditions</span></td></tr>
<tr>
<td>  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td>1.6</td>
<td>2.0</td>
</tr>
<tr><td><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and 
<span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td></tr>
<tr>
<td>  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td>2.1</td>
<td>2.2</td>
</tr>
<tr>
<td>  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td>3.3</td>
<td>3.7</td>
</tr>
<tr>
<td>  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td>2.8</td>
<td>2.9</td>
</tr>
<tr><td><span class="Italics">Musculoskeletal and connective 
tissue disorders</span></td></tr>
<tr>
<td>  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td>2.4</td>
<td>2.6</td>
</tr>
<tr>
<td>  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td>2.3</td>
<td>2.4</td>
</tr>
<tr>
<td>  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td>2.7</td>
<td>3.2</td>
</tr>
<tr class="Last">
<td>  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td>1.9</td>
<td>2.1</td>
</tr>
</tbody></table>*     All Statins = all dose of all statins<br><br><br><p><span class="Italics">Combination with Fenofibrate</span></p>
<p>This clinical study involving 625 patients with mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> (age range 
20–76 years, 44% women, 79% Caucasians, 0.1% Blacks, 11% Hispanics, 5% Asians) 
treated for up to 12 weeks and 576 patients treated for up to an additional 48 
weeks evaluated co-administration of ZETIA and fenofibrate. This study was not 
designed to compare treatment groups for infrequent events. Incidence rates (95% 
CI) for clinically important elevations (≥3 × ULN, consecutive) in hepatic 
transaminase levels were 4.5% (1.9, 8.8) and 2.7% (1.2, 5.4) for fenofibrate 
monotherapy (n=188) and ZETIA co-administered with fenofibrate (n=183), 
respectively, adjusted for treatment exposure. Corresponding incidence rates for 
cholecystectomy were 0.6% (95% CI: 0.0%, 3.1%) and 1.7% (95% CI: 0.6%, 4.0%) for 
fenofibrate monotherapy and ZETIA co-administered with fenofibrate, respectively 
<span class="Italics">[see <a href="#section-"> Drug Interactions (7.3)</a>]</span>. 
The numbers of patients exposed to co-administration therapy as well as 
fenofibrate and ezetimibe monotherapy were inadequate to assess gallbladder 
disease risk. There were no CPK elevations &gt;10 × ULN in any of the treatment 
groups.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>6.2 Post-Marketing Experience<p>Because the reactions below are reported voluntarily from a 
population of uncertain size, it is generally not possible to reliably estimate 
their frequency or establish a causal relationship to drug exposure.</p>
<p>The following additional adverse reactions have been identified during 
post-approval use of ZETIA:</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and 
<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; elevated creatine 
phosphokinase; <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> <span class="Italics">[see <a href="#section-"> Warnings and Precautions (5.3)</a>]</span>; elevations in liver 
transaminases; <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>; <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>; 
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>; <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>; 
<span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Z7"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">[See <a href="#S12.3">Clinical Pharmacology 
(12.3)</a>.]</span></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>7.1 Cyclosporine<p>Caution should be exercised when using ZETIA and cyclosporine 
concomitantly due to increased exposure to both ezetimibe and cyclosporine. 
Cyclosporine concentrations should be monitored in patients receiving ZETIA and 
cyclosporine.</p>
<p>The degree of increase in ezetimibe exposure may be greater in patients with 
severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. In patients treated with cyclosporine, the potential 
effects of the increased exposure to ezetimibe from concomitant use should be 
carefully weighed against the benefits of alterations in lipid levels provided 
by ezetimibe.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>7.2 Fibrates<p>The efficacy and safety of co-administration of ezetimibe with 
fibrates other than fenofibrate have not been studied.</p>
<p>Fibrates may increase <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> excretion into the bile, leading to 
<span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>. In a preclinical study in dogs, ezetimibe increased <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> 
in the gallbladder bile <span class="Italics">[see <a href="#S13.2">Nonclinical 
Toxicology (13.2)</a>]</span>. Co-administration of ZETIA with fibrates other 
than fenofibrate is not recommended until use in patients is adequately 
studied.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>7.3 Fenofibrate<p>If <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span> is suspected in a patient receiving ZETIA and 
fenofibrate, gallbladder studies are indicated and alternative lipid-lowering 
therapy should be considered <span class="Italics">[see <a href="#S6.1">Adverse 
Reactions (6.1)</a> and the product labeling for fenofibrate]</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>7.4 Cholestyramine<p>Concomitant cholestyramine administration decreased the mean area 
under the curve (AUC) of total ezetimibe approximately 55%. The incremental 
LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this 
interaction.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>7.5 Coumarin Anticoagulants<p>If ezetimibe is added to warfarin, a coumarin anticoagulant, the 
International Normalized Ratio (INR) should be appropriately monitored.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<p class="First">8.1 Pregnancy<a href="#section-"></a></p>
<p><span class="Italics">Pregnancy Category C:</span></p>
<p>There are no adequate and well-controlled studies of ezetimibe in pregnant 
women. Ezetimibe should be used during pregnancy only if the potential benefit 
justifies the risk to the fetus.</p>
<p>In oral (gavage) embryo-fetal development studies of ezetimibe conducted in 
rats and rabbits during organogenesis, there was no evidence of embryolethal 
effects at the doses tested (250, 500, 1000 mg/kg/day). In rats, increased 
incidences of common fetal skeletal findings (extra pair of thoracic ribs, 
unossified cervical vertebral centra, shortened ribs) were observed at 1000 
mg/kg/day (~10 × the human exposure at 10 mg daily based on AUC<span class="Sub">0–24hr</span> for total ezetimibe). In rabbits treated with ezetimibe, 
an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day 
(150 × the human exposure at 10 mg daily based on AUC<span class="Sub">0–24hr</span> for total ezetimibe). Ezetimibe crossed the placenta 
when pregnant rats and rabbits were given multiple oral doses.</p>
<p>Multiple-dose studies of ezetimibe given in combination with statins in rats 
and rabbits during organogenesis result in higher ezetimibe and statin 
exposures. Reproductive findings occur at lower doses in combination therapy 
compared to monotherapy. </p>
<p><span class="Bold">All statins are contraindicated in pregnant and nursing 
women. When ZETIA is administered with a statin in a woman of childbearing 
potential, refer to the pregnancy category and product labeling for the statin. 
<span class="Italics">[See <a href="#section-"> Contraindications (4)</a>.]</span></span></p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>8.3 Nursing Mothers<p>It is not known whether ezetimibe is excreted into human breast 
milk. In rat studies, exposure to total ezetimibe in nursing pups was up to half 
of that observed in maternal plasma. Because many drugs are excreted in human 
milk, caution should be exercised when ZETIA is administered to a nursing woman. 
ZETIA should not be used in nursing mothers unless the potential benefit 
justifies the potential risk to the infant.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>8.4 Pediatric Use<p>The effects of ZETIA co-administered with simvastatin (n=126) 
compared to simvastatin monotherapy (n=122) have been evaluated in adolescent 
boys and girls with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (HeFH). In a 
multicenter, double-blind, controlled study followed by an open-label phase, 142 
boys and 106 postmenarchal girls, 10 to 17 years of age (mean age 14.2 years, 
43% females, 82% Caucasians, 4% Asian, 2% Blacks, 13% multi-racial) with HeFH 
were randomized to receive either ZETIA co-administered with simvastatin or 
simvastatin monotherapy. Inclusion in the study required 1) a baseline LDL-C 
level between 160 and 400 mg/dL and 2) a medical history and clinical 
presentation consistent with HeFH. The mean baseline LDL-C value was 225 mg/dL 
(range: 161–351 mg/dL) in the ZETIA co-administered with simvastatin group 
compared to 219 mg/dL (range: 149–336 mg/dL) in the simvastatin monotherapy 
group. The patients received co-administered ZETIA and simvastatin (10 mg, 20 
mg, or 40 mg) or simvastatin monotherapy (10 mg, 20 mg, or 40 mg) for 6 weeks, 
co-administered ZETIA and 40 mg simvastatin or 40 mg simvastatin monotherapy for 
the next 27 weeks, and open-label co-administered ZETIA and simvastatin (10 mg, 
20 mg, or 40 mg) for 20 weeks thereafter.</p>
<p>The results of the study at Week 6 are summarized in <span class="Bold">Table 
3</span>. Results at Week 33 were consistent with those at Week 6.</p>
<a name="i1735b484-2cdc-46ec-8474-24aa7cd75ecc"></a><table width="100%">
<caption><span>TABLE
3: Mean Percent Difference at Week 6 Between the Pooled ZETIA
Co-Administered with Simvastatin Group and the Pooled Simvastatin
Monotherapy Group in Adolescent Patients with Heterozygous Familial
<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span></span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td>
<span class="Bold">Total-C</span><br>
</td>
<td>
<span class="Bold">LDL-C</span><br>
</td>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></span><br>
</td>
<td>
<span class="Bold">Non-HDL-C</span><br>
</td>
<td>
<span class="Bold">TG *</span><br>
</td>
<td>
<span class="Bold">HDL-C</span><br>
</td>
</tr>
<tr>
<td>Mean percent difference between treatment groups</td>
<td>-12%<br>
</td>
<td>-15%<br>
</td>
<td>-12%<br>
</td>
<td>-14%<br>
</td>
<td>-2%<br>
</td>
<td>+0.1%<br>
</td>
</tr>
<tr class="Last">
<td>95% Confidence Interval</td>
<td>(-15%, -9%)<br>
</td>
<td>(-18%, -12%)<br>
</td>
<td>(-15%, -9%)<br>
</td>
<td>(-17%, -11%)<br>
</td>
<td>(-9%, +4%)<br>
</td>
<td>(-3%, +3%)<br>
</td>
</tr>
</tbody>
</table>*     For triglycerides, median % change from baseline<br><br><br><p>From the start of the trial to the end of Week 33, discontinuations due to an 
adverse reaction occurred in 7 (6%) patients in the ZETIA co-administered with 
simvastatin group and in 2 (2%) patients in the simvastatin monotherapy 
group.</p>
<p>During the trial, hepatic transaminase elevations (two consecutive 
measurements for ALT and/or AST greater than or equal to 3 × ULN) occurred in four (3%) individuals in 
the ZETIA co-administered with simvastatin group and in two (2%) individuals in 
the simvastatin monotherapy group. Elevations of CPK (greater than or equal to 10 × ULN) occurred in two 
(2%) individuals in the ZETIA co-administered with simvastatin group and in zero 
individuals in the simvastatin monotherapy group.</p>
<p>In this limited controlled study, there was no significant effect on growth 
or sexual maturation in the adolescent boys or girls, or on menstrual cycle 
length in girls. </p>
<p>Co-administration of ZETIA with simvastatin at doses greater than 40 mg/day 
has not been studied in adolescents. Also, ZETIA has not been studied in 
patients younger than 10 years of age or in pre-menarchal girls.</p>
<p>Based on total ezetimibe (ezetimibe + ezetimibe-glucuronide), there are no 
pharmacokinetic differences between adolescents and adults. Pharmacokinetic data 
in the pediatric population less than 10 years of age are not available. </p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>8.5 Geriatric Use<a href="#section-"></a><p><span class="Italics">Monotherapy Studies</span></p>
<p>Of the 2396 patients who received ZETIA in clinical studies, 669 (28%) were 
65 and older, and 111 (5%) were 75 and older.</p>
<a href="#section-"></a><p><span class="Italics">Statin Co-Administration Studies</span></p>
<p>Of the 11,308 patients who received ZETIA + statin in clinical studies, 3587 
(32%) were 65 and older, and 924 (8%) were 75 and older.</p>
<p>No overall differences in safety and effectiveness were observed between 
these patients and younger patients, and other reported clinical experience has 
not identified differences in responses between the elderly and younger 
patients, but greater sensitivity of some older individuals cannot be ruled out 
<span class="Italics">[see <a href="#section-"> Clinical Pharmacology 
(12.3)</a>]</span>.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span><p>ZETIA is not recommended in patients with moderate to severe 
<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#section-"> Warnings and 
Precautions (5.4)</a></span> and <span class="Italics"><a href="#section-"> Clinical 
Pharmacology (12.3)</a>]</span>.</p>
<p>ZETIA given concomitantly with a statin is contraindicated in patients with 
active liver disease or unexplained persistent elevations of hepatic 
transaminase levels<span class="Italics"> [see <a href="#section-"> Contraindications 
(4)</a></span>; <span class="Italics"><a href="#section-"> Warnings and Precautions 
(5.2)</a>, and <a href="#section-"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">In clinical studies, administration of ezetimibe, 50 mg/day to 15 
healthy subjects for up to 14 days, or 40 mg/day to 18 patients with primary 
<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> for up to 56 days, was generally well tolerated.</p>
<p>A few cases of overdosage with ZETIA have been reported; most have not been 
associated with adverse experiences. Reported adverse experiences have not been 
serious. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, symptomatic and supportive measures should 
be employed.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">ZETIA (ezetimibe) is in a class of lipid-lowering compounds that 
selectively inhibits the intestinal absorption of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and related 
phytosterols. The chemical name of ezetimibe is 
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. 
The empirical formula is C<span class="Sub">24</span>H<span class="Sub">21</span>F<span class="Sub">2</span>NO<span class="Sub">3</span>. Its 
molecular weight is 409.4 and its structural formula is:</p>
<div class="Figure"><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb18564f-663f-4da2-9dd9-700ea9bdd398&amp;name=chemical%20structure.jpg"></div>
<p>Ezetimibe is a white, crystalline powder that is freely to very soluble in 
ethanol, methanol, and acetone and practically insoluble in water. Ezetimibe has 
a melting point of about 163°C and is stable at ambient temperature. ZETIA is 
available as a tablet for oral administration containing 10 mg of ezetimibe and 
the following inactive ingredients: croscarmellose sodium NF, lactose 
monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, povidone 
USP, and sodium lauryl sulfate NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<a href="#section-"></a>12.1 Mechanism of Action<p class="First">Ezetimibe reduces blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> by inhibiting the absorption 
of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> by the small intestine. In a 2-week clinical study in 18 
hypercholesterolemic patients, ZETIA inhibited intestinal <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption 
by 54%, compared with placebo. ZETIA had no clinically meaningful effect on the 
plasma concentrations of the fat-soluble vitamins A, D, and E (in a study of 113 
patients), and did not impair adrenocortical steroid hormone production (in a 
study of 118 patients).</p>
<p>The <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> content of the liver is derived predominantly from three 
sources. The liver can synthesize <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, take up <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> from the 
blood from circulating lipoproteins, or take up <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorbed by the 
small intestine. Intestinal <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is derived primarily from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> 
secreted in the bile and from dietary <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. </p>
<p>Ezetimibe has a mechanism of action that differs from those of other classes 
of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-reducing compounds (statins, bile acid sequestrants [resins], 
fibric acid derivatives, and plant stanols). The molecular target of ezetimibe 
has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), 
which is involved in the intestinal uptake of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and phytosterols.</p>
<p>Ezetimibe does not inhibit <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis in the liver, or increase 
bile acid excretion. Instead, ezetimibe localizes at the brush border of the 
small intestine and inhibits the absorption of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, leading to a 
decrease in the delivery of intestinal <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> to the liver. This causes a 
reduction of hepatic <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> stores and an increase in clearance of 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> from the blood; this distinct mechanism is complementary to that of 
statins and of fenofibrate <span class="Italics">[see <a href="#section-"> Clinical 
Studies (14.1)</a>]</span>.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>12.2 Pharmacodynamics<p>Clinical studies have demonstrated that elevated levels of 
total-C, LDL-C and <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, the major protein constituent of LDL, promote human 
<span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. In addition, decreased levels of HDL-C are associated with the 
development of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. Epidemiologic studies have established that 
cardiovascular morbidity and mortality vary directly with the level of total-C 
and LDL-C and inversely with the level of HDL-C. Like LDL, <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-enriched 
triglyceride-rich lipoproteins, including very-low-density lipoproteins (VLDL), 
intermediate-density lipoproteins (IDL), and remnants, can also promote 
<span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>. The independent effect of raising HDL-C or lowering TG on the 
risk of coronary and cardiovascular morbidity and mortality has not been 
determined.</p>
<p>ZETIA reduces total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and TG, and increases HDL-C in patients 
with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. Administration of ZETIA with a statin is effective in 
improving serum total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, TG, and HDL-C beyond either treatment 
alone. Administration of ZETIA with fenofibrate is effective in improving serum 
total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and non-HDL-C in patients with mixed <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> as 
compared to either treatment alone. The effects of ezetimibe given either alone 
or in addition to a statin or fenofibrate on cardiovascular morbidity and 
mortality have not been established.</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>12.3 Pharmacokinetics<a href="#section-"></a><p><span class="Italics">Absorption</span></p>
<p>After oral administration, ezetimibe is absorbed and extensively conjugated 
to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). 
After a single 10-mg dose of ZETIA to fasted adults, mean ezetimibe peak plasma 
concentrations (C<span class="Sub">max</span>) of 3.4 to 5.5 ng/mL were attained 
within 4 to 12 hours (T<span class="Sub">max</span>). Ezetimibe-glucuronide mean 
C<span class="Sub">max</span> values of 45 to 71 ng/mL were achieved between 1 and 
2 hours (T<span class="Sub">max</span>). There was no substantial deviation from 
dose proportionality between 5 and 20 mg. The absolute bioavailability of 
ezetimibe cannot be determined, as the compound is virtually insoluble in 
aqueous media suitable for injection. </p>
<a href="#section-"></a><p><span class="Italics">Effect of Food on Oral Absorption</span></p>
<p>Concomitant food administration (high-fat or non-fat meals) had no effect on 
the extent of absorption of ezetimibe when administered as ZETIA 10-mg tablets. 
The C<span class="Sub">max</span> value of ezetimibe was increased by 38% with 
consumption of high-fat meals. ZETIA can be administered with or without 
food.</p>
<a href="#section-"></a><p><span class="Italics">Distribution</span></p>
<p>Ezetimibe and ezetimibe-glucuronide are highly bound (greater than 90%) to human 
plasma proteins.</p>
<a href="#section-"></a><p><span class="Italics">Metabolism and Excretion</span></p>
<p>Ezetimibe is primarily metabolized in the small intestine and liver via 
glucuronide conjugation (a phase II reaction) with subsequent biliary and renal 
excretion. Minimal oxidative metabolism (a phase I reaction) has been observed 
in all species evaluated. </p>
<p>In humans, ezetimibe is rapidly metabolized to ezetimibe-glucuronide. 
Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds 
detected in plasma, constituting approximately 10 to 20% and 80 to 90% of the 
total drug in plasma, respectively. Both ezetimibe and ezetimibe-glucuronide are 
eliminated from plasma with a half-life of approximately 22 hours for both 
ezetimibe and ezetimibe-glucuronide. Plasma concentration-time profiles exhibit 
multiple peaks, suggesting enterohepatic recycling. </p>
<p>Following oral administration of <span class="Sup">14</span>C-ezetimibe (20 mg) 
to human subjects, total ezetimibe (ezetimibe + ezetimibe-glucuronide) accounted 
for approximately 93% of the total radioactivity in plasma. After 48 hours, 
there were no detectable levels of radioactivity in the plasma.</p>
<p>Approximately 78% and 11% of the administered radioactivity were recovered in 
the feces and urine, respectively, over a 10-day collection period. Ezetimibe 
was the major component in feces and accounted for 69% of the administered dose, 
while ezetimibe-glucuronide was the major component in urine and accounted for 
9% of the administered dose.</p>
<a href="#section-"></a><p><span class="Italics">Specific Populations</span></p>
<a href="#section-"></a><p><span class="Bold">Geriatric Patients:</span> In a multiple-dose 
study with ezetimibe given 10 mg once daily for 10 days, plasma concentrations 
for total ezetimibe were about 2-fold higher in older (greater than or equal to 65 years) healthy 
subjects compared to younger subjects.</p>
<a href="#section-"></a><p><span class="Bold">Pediatric Patients:</span><span class="Italics"> 
[See <a href="#section-"> Use in Specific Populations (8.4)</a>.]</span></p>
<a href="#section-"></a><p><span class="Bold">Gender:</span> In a multiple-dose study with 
ezetimibe given 10 mg once daily for 10 days, plasma concentrations for total 
ezetimibe were slightly higher (less than 20%) in women than in men. </p>
<a href="#section-"></a><p><span class="Bold">Race:</span> Based on a meta-analysis of 
multiple-dose pharmacokinetic studies, there were no pharmacokinetic differences 
between Black and Caucasian subjects. Studies in Asian subjects indicated that 
the pharmacokinetics of ezetimibe were similar to those seen in Caucasian 
subjects.</p>
<a href="#section-"></a><p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> After a single 10-mg 
dose of ezetimibe, the mean AUC for total ezetimibe was increased approximately 
1.7-fold in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 5 to 6), 
compared to healthy subjects. The mean AUC values for total ezetimibe and 
ezetimibe were increased approximately 3- to 4-fold and 5- to 6-fold, 
respectively, in patients with moderate (Child-Pugh score 7 to 9) or severe 
<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 10 to 15). In a 14-day, multiple-dose study 
(10 mg daily) in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the mean AUC values 
for total ezetimibe and ezetimibe were increased approximately 4-fold on Day 1 
and Day 14 compared to healthy subjects. Due to the unknown effects of the 
increased exposure to ezetimibe in patients with moderate or severe hepatic 
impairment, ZETIA is not recommended in these patients <span class="Italics">[see 
<a href="#section-"> Warnings and Precautions (5.4)</a>]</span>. </p>
<a href="#section-"></a><p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> After a single 10-mg 
dose of ezetimibe in patients with severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (n=8; mean CrCl less than or equal to 30 
mL/min/1.73 m<span class="Sup">2</span>), the mean AUC values for total ezetimibe, 
ezetimibe-glucuronide, and ezetimibe were increased approximately 1.5-fold, 
compared to healthy subjects (n=9). </p>
<a href="#section-"></a><p><span class="Italics">Drug Interactions [See also <a href="#section-"> Drug Interactions (7)</a>]</span></p>
<p>ZETIA had no significant effect on a series of probe drugs (caffeine, 
dextromethorphan, tolbutamide, and IV midazolam) known to be metabolized by 
cytochrome P450 (1A2, 2D6, 2C8/9 and 3A4) in a "cocktail" study of twelve 
healthy adult males. This indicates that ezetimibe is neither an inhibitor nor 
an inducer of these cytochrome P450 isozymes, and it is unlikely that ezetimibe 
will affect the metabolism of drugs that are metabolized by these enzymes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<a name="ib4548c34-7a13-49b1-8e7e-37774008b9e7"></a><table width="100%">
<caption><span>TABLE 4: Effect of Co-Administered Drugs on Total Ezetimibe</span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Co-Administered Drug and Dosing Regiment</span><br>
</td>
<td>
<span class="Bold">Total</span><br>
</td>
<td><span class="Bold"><span class="Bold">Ezetimibe <a href="#footnote-4">*</a></span></span></td>
</tr>
<tr>
<td><br></td>
<td>
<span class="Bold">Change in AUC</span><br>
</td>
<td>
<span class="Bold">Change in C<span class="Sub">max</span></span><span class="Sub"></span>
</td>
</tr>
<tr>
<td>Cyclosporine-stable dose required (75–150 mg BID)<a href="#footnote-5">†</a><span class="Sup">,</span><a href="#footnote-6">‡</a>
</td>
<td>↑240%</td>
<td>↑290%</td>
</tr>
<tr>
<td>Fenofibrate, 200 mg QD, 14 days<a href="#footnote-5">†</a>
</td>
<td>↑48%</td>
<td>↑64%</td>
</tr>
<tr>
<td>Gemfibrozil, 600 mg BID, 7 days<a href="#footnote-5">†</a>
</td>
<td>↑64%</td>
<td>↑91%</td>
</tr>
<tr>
<td>Cholestyramine, 4 g BID, 14 days<a href="#footnote-5">†</a>
</td>
<td>↓55%</td>
<td>↓4%</td>
</tr>
<tr>
<td>Aluminum &amp; magnesium hydroxide combination antacid, single dose<a href="#footnote-7">§</a>
</td>
<td>↓4%</td>
<td>↓30%</td>
</tr>
<tr>
<td>Cimetidine, 400 mg BID, 7 days</td>
<td>↑6%</td>
<td>↑22%</td>
</tr>
<tr>
<td>Glipizide, 10 mg, single dose</td>
<td>↑4%</td>
<td>↓8%</td>
</tr>
<tr>
<td><span class="Bold">Statins</span></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>  Lovastatin 20 mg QD, 7 days<br>
</td>
<td>↑9%</td>
<td>↑3%</td>
</tr>
<tr>
<td>  Pravastatin 20 mg QD, 14 days<br>
</td>
<td>↑7%</td>
<td>↑23%</td>
</tr>
<tr>
<td>  Atorvastatin 10 mg QD, 14 days<br>
</td>
<td>↓2%</td>
<td>↑12%</td>
</tr>
<tr>
<td>  Rosuvastatin 10 mg QD, 14 days<br>
</td>
<td>↑13%</td>
<td>↑18%</td>
</tr>
<tr class="Last">
<td>  Fluvastatin 20 mg QD, 14 days<br>
</td>
<td>↓19%</td>
<td>↑7%</td>
</tr>
</tbody>
</table>
<span class="Bold"><span class="Bold"></span></span><a href="http://SPLForm_DrugListing.xhtml#footnote-4">*</a>   Based on 10 mg dose of ezetimibe<br><a href="http://SPLForm_DrugListing.xhtml#footnote-5">†</a>   See <a href="#S7">Drug Interactions (7)</a><br><span class="Sup"></span><a href="http://SPLForm_DrugListing.xhtml#footnote-6">‡</a>   Post-renal transplant patients with mild impaired or normal renal function. In a 
different study, a renal transplant patient with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> 
(creatinine clearance of 13.2 mL/min/1.73 m<span class="Sup">2</span>) who was 
receiving multiple medications, including cyclosporine, demonstrated a 12-fold 
greater exposure to total ezetimibe compared to healthy subjects.<br><a href="http://SPLForm_DrugListing.xhtml#footnote-7">§</a>   Supralox, 20 mL<br><br><br><a name="i8799d2b9-1488-4a83-8898-6ff44601b169"></a><table width="100%">
<caption><span>TABLE 5: Effect of Ezetimibe Co-Administration on Systemic Exposure to Other Drugs</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Co-Administered Drug and its<br>Dosage Regiment<br></span></td>
<td>
<span class="Bold">Ezetimibe Dosage Regiment</span><br>
</td>
<td><span class="Bold">Change in AUC of Co-<br>Administered Drug<br></span></td>
<td>
<span class="Bold">Change in </span>C<span class="Sub">max</span><span class="Bold"> of Co-<br>Administered Drug<br></span>
</td>
</tr>
<tr>
<td>Warfarin, 25 mg single dose on day 7<br>
</td>
<td>10 mg QD, 11 days<br>
</td>
<td>↓2% (R-warfarin)<br>↓4% (S-warfarin)<br>
</td>
<td>↑3% (R-warfarin)<br>↑1% (S-warfarin)<br>
</td>
</tr>
<tr>
<td>Digoxin, 0.5 mg single dose<br>
</td>
<td>10 mg QD, 8 days<br>
</td>
<td>↑2%<br>
</td>
<td>↓7%</td>
</tr>
<tr>
<td>Gemfibrozil, 600 mg BID, 7 days<a href="#footnote-8">*</a>
</td>
<td>10 mg QD, 7 days<br>
</td>
<td>↓1%</td>
<td>↓11%</td>
</tr>
<tr>
<td>Ethinyl estradiol &amp; Levonorgestrel,<br>QD, 21 days<br>
</td>
<td>10 mg QD, days 8-14 of 21d oral<br>contraceptive cycle<br>
</td>
<td>Ethinyl estradiol<br>0%<br>Levonorgestrel<br>0%<br>
</td>
<td>Ethinyl estradiol<br>↓9%<br>Levonorgestrel<br>↓5%<br>
</td>
</tr>
<tr>
<td>Glipizide, 10 mg on days 1 and 9<br>
</td>
<td>10 mg QD, days 2-9<br>
</td>
<td>↓3%</td>
<td>↓5%</td>
</tr>
<tr>
<td>Fenofibrate, 200 mg QD, 14 days<a href="http://SPLForm_DrugListing.xhtml#footnote-8">*</a>
</td>
<td>10 mg QD, 14 days<br>
</td>
<td>↑11%</td>
<td>↑7%</td>
</tr>
<tr>
<td>Cyclosporine, 100 mg single dose day 7<a href="http://SPLForm_DrugListing.xhtml#footnote-8">*</a>
</td>
<td>20 mg QD, 8 days<br>
</td>
<td>↑15%</td>
<td>↑10%</td>
</tr>
<tr>
<td>
<span class="Bold">Statins</span><br>
</td>
<td><br></td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td>  Lovastatin 20 mg QD, 7 days<br>
</td>
<td>10 mg QD, 7 days<br>
</td>
<td>↑19%</td>
<td>3<br>
</td>
</tr>
<tr>
<td>  Pravastatin 20 mg QD, 14 days<br>
</td>
<td>10 mg QD, 14 days<br>
</td>
<td>↓20%</td>
<td>↓24%</td>
</tr>
<tr>
<td>  Atorvastatin 10 mg QD, 14 days<br>
</td>
<td>10 mg QD, 14 days<br>
</td>
<td>↓4%</td>
<td>↑7%</td>
</tr>
<tr>
<td>  Rosuvastatin 10 mg QD, 14 days<br>
</td>
<td>10 mg QD, 14 days<br>
</td>
<td>↑19%</td>
<td>↑17%</td>
</tr>
<tr class="Last">
<td>  Fluvastatin 20 mg QD, 14 days<br>
</td>
<td>10 mg QD, 14 days<br>
</td>
<td>↓39%</td>
<td>↓27%</td>
</tr>
</tbody>
</table>
<br><a href="http://SPLForm_DrugListing.xhtml#footnote-8">*</a>   See <a href="#S7">Drug Interactions (7)</a>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>13  NON CLINICAL TOXICOLOGY</h1>
<p class="First">13.1 Carcinogenesis, Mutagenesis, Impairment of 
Fertility</p>
<p>A 104-week dietary carcinogenicity study with ezetimibe was 
conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day 
(females) (~20 × the human exposure at 10 mg daily based on AUC<span class="Sub">0–24hr</span> for total ezetimibe). A 104-week dietary carcinogenicity 
study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day 
(&gt;150 × the human exposure at 10 mg daily based on AUC<span class="Sub">0–24hr</span> for total ezetimibe). There were no statistically 
significant increases in tumor incidences in drug-treated rats or mice. </p>
<p>No evidence of mutagenicity was observed <span class="Italics">in vitro 
</span>in a microbial mutagenicity (Ames) test with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium </span>and <span class="Italics">Escherichia 
coli </span>with or without metabolic activation. No evidence of clastogenicity 
was observed <span class="Italics">in vitro</span> in a chromosomal aberration 
assay in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> with or without metabolic 
activation. In addition, there was no evidence of genotoxicity in the <span class="Italics">in vivo </span>mouse micronucleus test.</p>
<p>In oral (gavage) fertility studies of ezetimibe conducted in rats, there was 
no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or 
female rats (~7 × the human exposure at 10 mg daily based on AUC<span class="Sub">0–24hr</span> for total ezetimibe).</p>
<a href="#section-"></a><a href="#section-"></a><a href="#section-"></a>13.2 Animal Toxicology and/or Pharmacology<p>The hypocholesterolemic effect of ezetimibe was evaluated in 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-fed Rhesus monkeys, dogs, rats, and mouse models of human 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> metabolism. Ezetimibe was found to have an ED<span class="Sub">50</span> value of 0.5 µg/kg/day for inhibiting the rise in plasma 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels in monkeys. The ED<span class="Sub">50</span> values in dogs, 
rats, and mice were 7, 30, and 700 µg/kg/day, respectively. These results are 
consistent with ZETIA being a potent <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption inhibitor.</p>
<p>In a rat model, where the glucuronide metabolite of ezetimibe (SCH 60663) was 
administered intraduodenally, the metabolite was as potent as the parent 
compound (SCH 58235) in inhibiting the absorption of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, suggesting 
that the glucuronide metabolite had activity similar to the parent drug.</p>
<p>In 1-month studies in dogs given ezetimibe (0.03 to 300 mg/kg/day), the 
concentration of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in gallbladder bile increased ~2- to 4-fold. 
However, a dose of 300 mg/kg/day administered to dogs for one year did not 
result in gallstone formation or any other adverse hepatobiliary effects. In a 
14-day study in mice given ezetimibe (0.3 to 5 mg/kg/day) and fed a low-fat or 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-rich diet, the concentration of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in gallbladder bile was 
either unaffected or reduced to normal levels, respectively.</p>
<p>A series of acute preclinical studies was performed to determine the 
selectivity of ZETIA for inhibiting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> absorption. Ezetimibe inhibited 
the absorption of <span class="Sup">14</span>C-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> with no effect on the 
absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl 
estradiol, or the fat-soluble vitamins A and D.</p>
<p>In 4- to 12-week toxicity studies in mice, ezetimibe did not induce 
cytochrome P450 drug metabolizing enzymes. In toxicity studies, a 
<span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> of ezetimibe with statins (parents or their active 
hydroxy acid metabolites) was seen in rats, dogs, and rabbits.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<a href="http://"></a>14.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span><p class="First">ZETIA reduces total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and TG, and increases HDL-C 
in patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>. Maximal to near maximal response is generally 
achieved within 2 weeks and maintained during chronic therapy.</p>
<a href="http://"></a><p><span class="Italics">Monotherapy</span></p>
<p>In two multicenter, double-blind, placebo-controlled, 12-week studies in 1719 
patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, ZETIA significantly lowered total-C, 
LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and TG, and increased HDL-C compared to placebo (see <span class="Bold"><a href="#table6">Table 6</a></span>). Reduction in LDL-C was 
consistent across age, sex, and baseline LDL-C.</p>
<a name="i2579b5c9-5058-4537-8fb2-29b4121cf8ee"></a><table width="100%">
<caption><span>TABLE 6: Response to ZETIA in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean* % Change from Untreated Baseline†) </span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td><span class="Bold">Treatment<br>Group<br></span></td>
<td>
<span class="Bold">N</span><br>
</td>
<td>
<span class="Bold">Total-C</span><br>
</td>
<td>
<span class="Bold">LDL-C</span><br>
</td>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></span><br>
</td>
<td>
<span class="Bold">TG</span><a href="#footnote-9">*</a>
</td>
<td>
<span class="Bold">HDL-C</span><br>
</td>
</tr>
<tr>
<td><span class="Bold">Study 1<a href="#footnote-11">‡</a><br></span></td>
<td>Placebo<br>Ezetimibe<br>
</td>
<td>205<br>622<br>
</td>
<td>+1<br>-12<br>
</td>
<td>+1<br>-18<br>
</td>
<td>-1<br>-15<br>
</td>
<td>-1<br>-7<br>
</td>
<td>-1<br>+1<br>
</td>
</tr>
<tr>
<td><span class="Bold">Study 2<a href="#footnote-11">‡</a></span></td>
<td>Placebo<br>
Ezetimibe</td>
<td>226<br>666<br>
</td>
<td>+1<br>-12<br>
</td>
<td>+1<br>-18<br>
</td>
<td>-1<br>-16<br>
</td>
<td>+2<br>-9<br>
</td>
<td>-2<br>+1<br>
</td>
</tr>
<tr class="Last">
<td><span class="Bold">Pooled Data<a href="#footnote-11">‡</a> (Studies<br>1 &amp; 2)<br></span></td>
<td>Placebo<br>
Ezetimibe</td>
<td>431<br>1288<br>
</td>
<td>0<br>-13<br>
</td>
<td>+1<br>-18<br>
</td>
<td>-2<br>-16<br>
</td>
<td>0<br>-8<br>
</td>
<td>-2<br>+1<br>
</td>
</tr>
</tbody>
</table>
<a href="#footnote-9">*</a>   For triglycerides, median % change from baseline<br><a href="#footnote-10">†</a>   Baseline - on no lipid-lowering drug<br><span class="Bold"><a href="http://SPLForm_DrugListing.xhtml#footnote-11">‡</a></span>   ZETIA significantly reduced total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and TG, and increased HDL-C 
compared to placebo.<br><br><br><p><span class="Italics">Combination with Statins</span></p>
<a href="http://"></a><p><span class="Italics">ZETIA Added to On-going Statin Therapy</span></p>
<p>In a multicenter, double-blind, placebo-controlled, 8-week study, 769 
patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, known coronary heart disease or multiple 
cardiovascular risk factors who were already receiving statin monotherapy, but 
who had not met their NCEP ATP II target LDL-C goal were randomized to receive 
either ZETIA or placebo in addition to their on-going statin. </p>
<p>ZETIA, added to on-going statin therapy, significantly lowered total-C, 
LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and TG, and increased HDL-C compared with a statin administered 
alone (see <span class="Bold"><a href="#table7">Table 7</a></span>). LDL-C 
reductions induced by ZETIA were generally consistent across all statins.</p>
<a name="i01d68631-d4a9-401b-8b7c-70f4a32233b8"></a><table width="80%">
<caption><span>TABLE 7: Response to Addition of ZETIA to On-Going Statin Therapy* in Patients with <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean† % Change from Treated Baseline‡)</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Treatment (Daily<br>Dose)<br></span></td>
<td>
<span class="Bold">N</span><br>
</td>
<td>
<span class="Bold">Total-C</span><br>
</td>
<td>
<span class="Bold">LDL-C</span><br>
</td>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></span><br>
</td>
<td>
<span class="Bold">TG</span><a href="#footnote-13">†</a>
</td>
<td>
<span class="Bold">HDL-C</span><br>
</td>
</tr>
<tr>
<td>On-going Statin +<br>Placebo<a href="#footnote-15">§</a><br>
</td>
<td>390<br>
</td>
<td>-2<br>
</td>
<td>-4<br>
</td>
<td>-3<br>
</td>
<td>-3<br>
</td>
<td>+1<br>
</td>
</tr>
<tr class="Last">
<td>On-going Statin +<br>ZETIA<a href="#footnote-15">§</a><br>
</td>
<td>379<br>
</td>
<td>-17<br>
</td>
<td>-25<br>
</td>
<td>-19<br>
</td>
<td>-14<br>
</td>
<td>+3<br>
</td>
</tr>
</tbody>
</table>
<a href="http://SPLForm_DrugListing.xhtml#footnote-9">*</a>   Patients receiving each statin: 40% atorvastatin, 31% simvastatin, 29% others 
(pravastatin, fluvastatin, cerivastatin, lovastatin)<br><a href="http://SPLForm_DrugListing.xhtml#footnote-10">†</a>   For triglycerides, median % change from baseline<br><span class="Bold"><a href="http://SPLForm_DrugListing.xhtml#footnote-11">‡</a></span>   Baseline - on a statin alone.<br><a href="http://SPLForm_DrugListing.xhtml#footnote-15">§</a>   <br>ZETIA + statin significantly reduced total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and TG, and 
increased HDL-C compared to statin alone.<br><br><p><span class="Italics">ZETIA Initiated Concurrently with a 
Statin</span></p>
<p>In four multicenter, double-blind, placebo-controlled, 12-week trials, in 
2382 hyperlipidemic patients, ZETIA or placebo was administered alone or with 
various doses of atorvastatin, simvastatin, pravastatin, or lovastatin.</p>
<p>When all patients receiving ZETIA with a statin were compared to all those 
receiving the corresponding statin alone, ZETIA significantly lowered total-C, 
LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and TG, and, with the exception of pravastatin, increased HDL-C 
compared to the statin administered alone. LDL-C reductions induced by ZETIA 
were generally consistent across all statins. (See footnote <a href="#footnote-18">‡</a>, <span class="Bold">Tables 8 </span>to<span class="Bold"> 
11</span>.)</p>
<a name="i9d76e910-bf23-4991-8fd0-0db66b7cc62a"></a><table width="80%">
<caption><span>TABLE 8: Response to ZETIA and Atorvastatin Initiated Concurrently in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean* % Change from Untreated Baseline†)</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Treatment (Daily<br>
Dose)</span></td>
<td>
<span class="Bold">N</span><br>
</td>
<td>
<span class="Bold">Total-C</span><br>
</td>
<td>
<span class="Bold">LDL-C</span><br>
</td>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></span><br>
</td>
<td>
<span class="Bold">TG</span><a href="http://SPLForm_DrugListing.xhtml#footnote-9">*</a>
</td>
<td>
<span class="Bold">HDL-C</span><br>
</td>
</tr>
<tr>
<td>Placebo<br>
</td>
<td>60<br>
</td>
<td>+4<br>
</td>
<td>+4<br>
</td>
<td>+3<br>
</td>
<td>-6<br>
</td>
<td>+4<br>
</td>
</tr>
<tr>
<td>ZETIA<br>
</td>
<td>65<br>
</td>
<td>-14<br>
</td>
<td>-20<br>
</td>
<td>-15<br>
</td>
<td>-5<br>
</td>
<td>+4<br>
</td>
</tr>
<tr>
<td>Atorvastatin 10 mg<br>
</td>
<td>60<br>
</td>
<td>-26<br>
</td>
<td>-37<br>
</td>
<td>-28<br>
</td>
<td>-21<br>
</td>
<td>+6<br>
</td>
</tr>
<tr>
<td>ZETIA + Atorvastatin 10 mg<br>
</td>
<td>65<br>
</td>
<td>-38<br>
</td>
<td>-53<br>
</td>
<td>-43<br>
</td>
<td>-31<br>
</td>
<td>+9<br>
</td>
</tr>
<tr>
<td>Atorvastatin 20 mg<br>
</td>
<td>60<br>
</td>
<td>-30<br>
</td>
<td>-42<br>
</td>
<td>-34<br>
</td>
<td>-23<br>
</td>
<td>+4<br>
</td>
</tr>
<tr>
<td>ZETIA + Atorvastatin 20 mg</td>
<td>62<br>
</td>
<td>-39<br>
</td>
<td>-54<br>
</td>
<td>-44<br>
</td>
<td>-30<br>
</td>
<td>+9<br>
</td>
</tr>
<tr>
<td>Atorvastatin 40 mg<br>
</td>
<td>66<br>
</td>
<td>-32<br>
</td>
<td>-45<br>
</td>
<td>-37<br>
</td>
<td>-24<br>
</td>
<td>+4<br>
</td>
</tr>
<tr>
<td>ZETIA + Atorvastatin 40 mg</td>
<td>65<br>
</td>
<td>-42<br>
</td>
<td>-56<br>
</td>
<td>-45<br>
</td>
<td>-34<br>
</td>
<td>+5<br>
</td>
</tr>
<tr>
<td>Atorvastatin 80 mg<br>
</td>
<td>62<br>
</td>
<td>-40<br>
</td>
<td>-54<br>
</td>
<td>-46<br>
</td>
<td>-31<br>
</td>
<td>+3<br>
</td>
</tr>
<tr>
<td>ZETIA + Atorvastatin 80 mg</td>
<td>63<br>
</td>
<td>-46<br>
</td>
<td>-61<br>
</td>
<td>-50<br>
</td>
<td>-40<br>
</td>
<td>+7<br>
</td>
</tr>
<tr>
<td>Pooled data (All Atorvastatin Doses)<a href="#footnote-18">‡</a>
</td>
<td>248<br>
</td>
<td>-32<br>
</td>
<td>-44<br>
</td>
<td>-36<br>
</td>
<td>-24<br>
</td>
<td>+4<br>
</td>
</tr>
<tr class="Last">
<td>Pooled data (All ZETIA +<br>Atorvastatin Doses)<a href="#footnote-18">‡</a>
</td>
<td>255<br>
</td>
<td>-41<br>
</td>
<td>-56<br>
</td>
<td>-45<br>
</td>
<td>-33<br>
</td>
<td>+7<br>
</td>
</tr>
</tbody>
</table>
<a href="http://SPLForm_DrugListing.xhtml#footnote-9">*</a>   For triglycerides, median % change from baseline<br><a href="http://SPLForm_DrugListing.xhtml#footnote-10">†</a>   Baseline - on no lipid-lowering drug<br><span class="Bold"><a href="http://SPLForm_DrugListing.xhtml#footnote-11">‡</a></span>   <br>ZETIA + all doses of atorvastatin pooled (10–80 mg) significantly reduced 
total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and TG, and increased HDL-C compared to all doses of 
atorvastatin pooled (10–80 mg).<br><br><a name="i798d765b-84bb-4700-862e-05edc1639192"></a><table width="80%">
<caption><span>TABLE 9: Response to ZETIA and Simvastatin Initiated Concurrently in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean* % Change from Untreated Baseline†)</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Treatment (Daily<br>
Dose)</span></td>
<td>
<span class="Bold">N</span><br>
</td>
<td>
<span class="Bold">Total-C</span><br>
</td>
<td>
<span class="Bold">LDL-C</span><br>
</td>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></span><br>
</td>
<td>
<span class="Bold">TG</span><a href="http://SPLForm_DrugListing.xhtml#footnote-9">*</a>
</td>
<td>
<span class="Bold">HDL-C</span><span class="Bold"></span>
</td>
</tr>
<tr>
<td>Placebo<br>
</td>
<td>70<br>
</td>
<td>-1<br>
</td>
<td>-1<br>
</td>
<td>0<br>
</td>
<td>+2<br>
</td>
<td>+1<br>
</td>
</tr>
<tr>
<td>ZETIA<br>
</td>
<td>61<br>
</td>
<td>-13<br>
</td>
<td>-19<br>
</td>
<td>-14<br>
</td>
<td>-11<br>
</td>
<td>+5<br>
</td>
</tr>
<tr>
<td>Simvastatin 10 mg<br>
</td>
<td>70<br>
</td>
<td>-18<br>
</td>
<td>-27<br>
</td>
<td>-21<br>
</td>
<td>-14<br>
</td>
<td>+8<br>
</td>
</tr>
<tr>
<td>ZETIA + Simvastatin 10 mg<br>
</td>
<td>67<br>
</td>
<td>-32<br>
</td>
<td>-46<br>
</td>
<td>-35<br>
</td>
<td>-26<br>
</td>
<td>+9<br>
</td>
</tr>
<tr>
<td>Simvastatin 20 mg</td>
<td>61<br>
</td>
<td>-26<br>
</td>
<td>-36<br>
</td>
<td>-29<br>
</td>
<td>-18<br>
</td>
<td>+6<br>
</td>
</tr>
<tr>
<td>ZETIA + Simvastatin 20 mg</td>
<td>69<br>
</td>
<td>-33<br>
</td>
<td>-46<br>
</td>
<td>-36<br>
</td>
<td>-25<br>
</td>
<td>+9<br>
</td>
</tr>
<tr>
<td>Simvastatin 40 mg</td>
<td>65<br>
</td>
<td>-27<br>
</td>
<td>-38<br>
</td>
<td>-32<br>
</td>
<td>-24<br>
</td>
<td>+6<br>
</td>
</tr>
<tr>
<td>ZETIA + Simvastatin 40 mg</td>
<td>73<br>
</td>
<td>-40<br>
</td>
<td>-56<br>
</td>
<td>-45<br>
</td>
<td>-32<br>
</td>
<td>+11<br>
</td>
</tr>
<tr>
<td>Simvastatin 80 mg</td>
<td>67<br>
</td>
<td>-32<br>
</td>
<td>-45<br>
</td>
<td>-37<br>
</td>
<td>-23<br>
</td>
<td>+8<br>
</td>
</tr>
<tr>
<td>ZETIA + Simvastatin 80 mg</td>
<td>65<br>
</td>
<td>-41<br>
</td>
<td>-58<br>
</td>
<td>-47<br>
</td>
<td>-31<br>
</td>
<td>+8<br>
</td>
</tr>
<tr>
<td>Pooled data (All Simvastatin Doses)<a href="http://SPLForm_DrugListing.xhtml#footnote-18">‡</a>
</td>
<td>263<br>
</td>
<td>-26<br>
</td>
<td>-36<br>
</td>
<td>-30<br>
</td>
<td>-20<br>
</td>
<td>+7<br>
</td>
</tr>
<tr class="Last">
<td>Pooled data (All ZETIA +<br>Simvastatin Doses)<a href="http://SPLForm_DrugListing.xhtml#footnote-18">‡</a>
</td>
<td>274<br>
</td>
<td>-37<br>
</td>
<td>-51<br>
</td>
<td>-41<br>
</td>
<td>-29<br>
</td>
<td>+9<br>
</td>
</tr>
</tbody>
</table>
<a href="http://SPLForm_DrugListing.xhtml#footnote-9"></a><a href="http://SPLForm_DrugListing.xhtml#footnote-9">*</a>   For triglycerides, median % change from baseline<br><a href="http://SPLForm_DrugListing.xhtml#footnote-10">†</a>   Baseline - on no lipid-lowering drug<br><span class="Bold"><a href="http://SPLForm_DrugListing.xhtml#footnote-11">‡</a></span>   <br>ZETIA + all doses of simvastatin pooled (10–80 mg) significantly reduced 
total-C, LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and TG, and increased HDL-C compared to all doses of 
simvastatin pooled (10–80 mg).<br><br><a name="i8a5a5169-2fef-4181-852f-0a9b6bea4302"></a><table width="80%">
<caption><span>TABLE 10: Response to ZETIA and Pravastatin Initiated Concurrently in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean* % Change from Untreated Baseline†)</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Treatment<br>(Daily Dose)<br></span></td>
<td>
<span class="Bold">N</span><br>
</td>
<td>
<span class="Bold">Total-C</span><br>
</td>
<td>
<span class="Bold">LDL-C</span><br>
</td>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></span><br>
</td>
<td>
<span class="Bold">TG</span><a href="http://SPLForm_DrugListing.xhtml#footnote-9">*</a>
</td>
<td>
<span class="Bold">HDL-C</span><br>
</td>
</tr>
<tr>
<td>Placebo<br>
</td>
<td>65<br>
</td>
<td>0<br>
</td>
<td>-1<br>
</td>
<td>-2<br>
</td>
<td>-1<br>
</td>
<td>+2<br>
</td>
</tr>
<tr>
<td>ZETIA<br>
</td>
<td>64<br>
</td>
<td>-13<br>
</td>
<td>-20<br>
</td>
<td>-15<br>
</td>
<td>-5<br>
</td>
<td>+4<br>
</td>
</tr>
<tr>
<td>Pravastatin 10 mg<br>
</td>
<td>66<br>
</td>
<td>-15<br>
</td>
<td>-21<br>
</td>
<td>-16<br>
</td>
<td>-14<br>
</td>
<td>+6<br>
</td>
</tr>
<tr>
<td>ZETIA + Pravastatin 10 mg<br>
</td>
<td>71<br>
</td>
<td>-24<br>
</td>
<td>-34<br>
</td>
<td>-27<br>
</td>
<td>-23<br>
</td>
<td>+8<br>
</td>
</tr>
<tr>
<td>Pravastatin 20 mg</td>
<td>69<br>
</td>
<td>-15<br>
</td>
<td>-23<br>
</td>
<td>-18<br>
</td>
<td>-8<br>
</td>
<td>+8<br>
</td>
</tr>
<tr>
<td>ZETIA + Pravastatin 20 mg</td>
<td>66<br>
</td>
<td>-27<br>
</td>
<td>-40<br>
</td>
<td>-31<br>
</td>
<td>-21<br>
</td>
<td>+8<br>
</td>
</tr>
<tr>
<td>Pravastatin 40 mg</td>
<td>70<br>
</td>
<td>-22<br>
</td>
<td>-31<br>
</td>
<td>-26<br>
</td>
<td>-19<br>
</td>
<td>+6<br>
</td>
</tr>
<tr>
<td>ZETIA + Pravastatin 40 mg</td>
<td>67<br>
</td>
<td>-30<br>
</td>
<td>-42<br>
</td>
<td>-32<br>
</td>
<td>-21<br>
</td>
<td>+8<br>
</td>
</tr>
<tr>
<td>Pooled data (All Pravastatin Doses)<a href="http://SPLForm_DrugListing.xhtml#footnote-18">‡</a>
</td>
<td>205<br>
</td>
<td>-17<br>
</td>
<td>-25<br>
</td>
<td>-20<br>
</td>
<td>-14<br>
</td>
<td>+7<br>
</td>
</tr>
<tr class="Last">
<td>Pooled data (All ZETIA + <br>Pravastatin Doses)<a href="http://SPLForm_DrugListing.xhtml#footnote-18">‡</a>
</td>
<td>204<br>
</td>
<td>-27<br>
</td>
<td>-39<br>
</td>
<td>-30<br>
</td>
<td>-21<br>
</td>
<td>+8<br>
</td>
</tr>
</tbody>
</table>
<a href="http://SPLForm_DrugListing.xhtml#footnote-9">*</a>   For triglycerides, median % change from baseline<br><a href="http://SPLForm_DrugListing.xhtml#footnote-10">†</a>   Baseline - on no lipid-lowering drug<br><span class="Bold"><a href="http://SPLForm_DrugListing.xhtml#footnote-11">‡</a></span>   ZETIA + all doses of pravastatin pooled (10–40 mg) significantly reduced total-C, 
LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and TG compared to all doses of pravastatin pooled (10–40 mg).<br><br><a href="#footnote-15"></a><br><a name="ia01b09c1-f9eb-48a7-82c0-df6db4462f2f"></a><table width="80%">
<caption><span>TABLE 11: Response to ZETIA and Lovastatin Initiated Concurrently in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean* % Change from Untreated Baseline†)</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Treatment<br>
(Daily Dose)</span></td>
<td>
<span class="Bold">N</span><br>
</td>
<td>
<span class="Bold">Total-C</span><br>
</td>
<td>
<span class="Bold">LDL-C</span><br>
</td>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></span><br>
</td>
<td>
<span class="Bold">TG</span><a href="http://SPLForm_DrugListing.xhtml#footnote-9">*</a>
</td>
<td>
<span class="Bold">HDL-C</span><br>
</td>
</tr>
<tr>
<td>Placebo<br>
</td>
<td>64<br>
</td>
<td>+1<br>
</td>
<td>0<br>
</td>
<td>+1<br>
</td>
<td>+6<br>
</td>
<td>0<br>
</td>
</tr>
<tr>
<td>ZETIA<br>
</td>
<td>72<br>
</td>
<td>-13<br>
</td>
<td>-19<br>
</td>
<td>-14<br>
</td>
<td>-5<br>
</td>
<td>+3<br>
</td>
</tr>
<tr>
<td>Lovastatin 10 mg<br>
</td>
<td>73<br>
</td>
<td>-15<br>
</td>
<td>-20<br>
</td>
<td>-17<br>
</td>
<td>-11<br>
</td>
<td>+5<br>
</td>
</tr>
<tr>
<td>ZETIA + Lovastatin 10 mg</td>
<td>65<br>
</td>
<td>-24<br>
</td>
<td>-34<br>
</td>
<td>-27<br>
</td>
<td>-19<br>
</td>
<td>+8<br>
</td>
</tr>
<tr>
<td>Lovastatin 20 mg<br>
</td>
<td>74<br>
</td>
<td>-19<br>
</td>
<td>-26<br>
</td>
<td>-21<br>
</td>
<td>-12<br>
</td>
<td>+3<br>
</td>
</tr>
<tr>
<td>ZETIA + Lovastatin 20 mg</td>
<td>62<br>
</td>
<td>-29<br>
</td>
<td>-41<br>
</td>
<td>-34<br>
</td>
<td>-27<br>
</td>
<td>+9<br>
</td>
</tr>
<tr>
<td>Lovastatin 40 mg<br>
</td>
<td>73<br>
</td>
<td>-21<br>
</td>
<td>-30<br>
</td>
<td>-25<br>
</td>
<td>-15<br>
</td>
<td>+5<br>
</td>
</tr>
<tr>
<td>ZETIA + Lovastatin 40 mg<br>
</td>
<td>65<br>
</td>
<td>-33<br>
</td>
<td>-46<br>
</td>
<td>-38<br>
</td>
<td>-27<br>
</td>
<td>+9<br>
</td>
</tr>
<tr>
<td>Pooled data (All Lovastatin Doses)<a href="http://SPLForm_DrugListing.xhtml#footnote-18">‡</a>
</td>
<td>220<br>
</td>
<td>-18<br>
</td>
<td>-25<br>
</td>
<td>-21<br>
</td>
<td>-12<br>
</td>
<td>+4<br>
</td>
</tr>
<tr class="Last">
<td>Pooled data (All ZETIA + <br>Lovastatin Doses)<a href="http://SPLForm_DrugListing.xhtml#footnote-18">‡</a>
</td>
<td>192<br>
</td>
<td>-29<br>
</td>
<td>-40<br>
</td>
<td>-33<br>
</td>
<td>-25<br>
</td>
<td>+9<br>
</td>
</tr>
</tbody>
</table>
<br><a href="http://SPLForm_DrugListing.xhtml#footnote-9">*</a>   For triglycerides, median % change from baseline<br><a href="http://SPLForm_DrugListing.xhtml#footnote-10">†</a>   Baseline - on no lipid-lowering drug<br><span class="Bold"><a href="http://SPLForm_DrugListing.xhtml#footnote-11">‡</a></span>   ZETIA + all doses of lovastatin pooled (10–40 mg) significantly reduced total-C, 
LDL-C, <span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and TG, and increased HDL-C compared to all doses of lovastatin 
pooled (10–40 mg).<p><span class="Italics"><br></span></p>
<p><span class="Italics">Combination with Fenofibrate</span></p>
<p>In a multicenter, double-blind, placebo-controlled, clinical study in 
patients with mixed <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, 625 patients were treated for up to 12 weeks 
and 576 for up to an additional 48 weeks. Patients were randomized to receive 
placebo, ZETIA alone, 160 mg fenofibrate alone, or ZETIA and 160 mg fenofibrate 
in the 12-week study. After completing the 12-week study, eligible patients were 
assigned to ZETIA co-administered with fenofibrate or fenofibrate monotherapy 
for an additional 48 weeks.</p>
<p>ZETIA co-administered with fenofibrate significantly lowered total-C, LDL-C, 
<span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>, and non-HDL-C compared to fenofibrate administered alone. The percent 
decrease in TG and percent increase in HDL-C for ZETIA co-administered with 
fenofibrate were comparable to those for fenofibrate administered alone (see 
<span class="Bold"><a href="#table12">Table 12</a></span>).</p>
<a name="idce60d9a-63f4-484b-8c78-5379c3223dba"></a><table width="80%">
<caption><span>TABLE 12: Response to ZETIA and Fenofibrate Initiated Concurrently in Patients with Mixed <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> (Mean* % Change from Untreated Baseline† at 12 weeks)</span></caption>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Treatment<br>(Daily Dose)<br></span></td>
<td>
<span class="Bold">N</span><br>
</td>
<td>
<span class="Bold">Total-C</span><br>
</td>
<td>
<span class="Bold">LDL-C</span><br>
</td>
<td>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span></span><br>
</td>
<td>
<span class="Bold">TG</span><a href="http://SPLForm_DrugListing.xhtml#footnote-9">*</a>
</td>
<td>
<span class="Bold">HDL-C</span><br>
</td>
<td>
<span class="Bold">Non-HDL-C</span><br>
</td>
</tr>
<tr>
<td>Placebo<br>
</td>
<td>63<br>
</td>
<td>0<br>
</td>
<td>0<br>
</td>
<td>-1<br>
</td>
<td>-9<br>
</td>
<td>+3<br>
</td>
<td>0<br>
</td>
</tr>
<tr>
<td>ZETIA<br>
</td>
<td>185<br>
</td>
<td>-12<br>
</td>
<td>-13<br>
</td>
<td>-11<br>
</td>
<td>-11<br>
</td>
<td>+4<br>
</td>
<td>-15<br>
</td>
</tr>
<tr>
<td>Fenofibrate 160 mg<br>
</td>
<td>188<br>
</td>
<td>-11<br>
</td>
<td>-6<br>
</td>
<td>-15<br>
</td>
<td>-43<br>
</td>
<td>+19<br>
</td>
<td>-16<br>
</td>
</tr>
<tr class="Last">
<td>ZETIA + Fenofibrate 160 mg<br>
</td>
<td>183<br>
</td>
<td>-22<br>
</td>
<td>-20<br>
</td>
<td>-26<br>
</td>
<td>-44<br>
</td>
<td>+19<br>
</td>
<td>-30<br>
</td>
</tr>
</tbody>
</table>
<a href="http://SPLForm_DrugListing.xhtml#footnote-9">*</a>   For triglycerides, median % change from baseline<br><a href="http://SPLForm_DrugListing.xhtml#footnote-10">†</a>   Baseline - on no lipid-lowering drug<br><br><br>The changes in lipid endpoints after an additional 48 weeks of treatment with 
ZETIA co-administered with fenofibrate or with fenofibrate alone were consistent 
with the 12-week data displayed above.<br><br><a href="http://"></a>14.2 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span> 
(HoFH)<p>A study was conducted to assess the efficacy of ZETIA in the 
treatment of HoFH. This double-blind, randomized, 12-week study enrolled 50 
patients with a clinical and/or genotypic diagnosis of HoFH, with or without 
concomitant LDL apheresis, already receiving atorvastatin or simvastatin (40 
mg). Patients were randomized to one of three treatment groups, atorvastatin or 
simvastatin (80 mg), ZETIA administered with atorvastatin or simvastatin (40 
mg), or ZETIA administered with atorvastatin or simvastatin (80 mg). Due to 
decreased bioavailability of ezetimibe in patients concomitantly receiving 
cholestyramine <span class="Italics">[see <a href="#S7.1">Drug Interactions 
(7.1)</a>]</span>, ezetimibe was dosed at least 4 hours before or after 
administration of resins. Mean baseline LDL-C was 341 mg/dL in those patients 
randomized to atorvastatin 80 mg or simvastatin 80 mg alone and 316 mg/dL in the 
group randomized to ZETIA plus atorvastatin 40 or 80 mg or simvastatin 40 or 80 
mg. ZETIA, administered with atorvastatin or simvastatin (40 and 80 mg statin 
groups, pooled), significantly reduced LDL-C (21%) compared with increasing the 
dose of simvastatin or atorvastatin monotherapy from 40 to 80 mg (7%). In those 
treated with ZETIA plus 80 mg atorvastatin or with ZETIA plus 80 mg simvastatin, 
LDL-C was reduced by 27%.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>14.3 Homozygous Sitosterolemia (Phytosterolemia)<p>A study was conducted to assess the efficacy of ZETIA in the 
treatment of homozygous sitosterolemia. In this multicenter, double-blind, 
placebo-controlled, 8-week trial, 37 patients with homozygous sitosterolemia 
with elevated plasma sitosterol levels (greater than 5 mg/dL) on their current 
therapeutic regimen (diet, bile-acid-binding resins, statins, ileal bypass 
surgery and/or LDL apheresis), were randomized to receive ZETIA (n=30) or 
placebo (n=7). Due to decreased bioavailability of ezetimibe in patients 
concomitantly receiving cholestyramine <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>]</span>, ezetimibe was dosed at least 2 
hours before or 4 hours after resins were administered. Excluding the one 
subject receiving LDL apheresis, ZETIA significantly lowered plasma sitosterol 
and campesterol, by 21% and 24% from baseline, respectively. In contrast, 
patients who received placebo had increases in sitosterol and campesterol of 4% 
and 3% from baseline, respectively. For patients treated with ZETIA, mean plasma 
levels of plant sterols were reduced progressively over the course of the study. 
The effects of reducing plasma sitosterol and campesterol on reducing the risks 
of cardiovascular morbidity and mortality have not been established.</p>
<p>Reductions in sitosterol and campesterol were consistent between patients 
taking ZETIA concomitantly with bile acid sequestrants (n=8) and patients not on 
concomitant bile acid sequestrant therapy (n=21).</p>
<a href="http://"></a><p><span class="Bold">Limitations of Use</span></p>
<p>The effect of ZETIA on cardiovascular morbidity and mortality has not been 
determined.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">No. 3861 — Tablets ZETIA, 10 mg, are white to off-white, 
capsule-shaped tablets debossed with "414" on one side. They are supplied as 
follows: </p>
<p><span class="Bold">NDC</span> 54868-4719-1 bottles of 30<br><span class="Bold">NDC</span> 54868-4719-0 bottles of 90<span class="Bold">.</span></p>
<a href="#section-"></a><p><span><br></span></p>
<p><span>Storage</span></p>
<p>Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F). [See USP 
Controlled Room Temperature.] Protect from moisture. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Z17"></a><a name="section-16"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">[See <a href="#S17.5">FDA-approved Patient 
Labeling (17.5)</a>.]</span></p>
<p>Patients should be advised to adhere to their National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education 
Program (NCEP)-recommended diet, a regular exercise program, and periodic 
testing of a fasting lipid panel.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<h2>17.1  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span></h2>
<p class="First">All patients starting therapy with ezetimibe should be advised of the risk of 
<span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and told to report promptly any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or 
<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. The risk of this occurring is increased when taking certain types of 
medication. Patients should discuss all medication, both prescription and 
over-the-counter, with their physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<h2>17.2  Liver Enzymes</h2>
<p class="First">Liver tests should be performed when ZETIA is added to statin therapy and 
according to statin recommendations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.3"></a><p></p>
<h2>17.3  Pregnancy</h2>
<p class="First">Women of childbearing age should be advised to use an effective method of birth 
control to prevent pregnancy while using ZETIA added to statin therapy. Discuss 
future pregnancy plans with your patients, and discuss when to stop combination 
ZETIA and statin therapy if they are trying to conceive. Patients should be 
advised that if they become pregnant they should stop taking combination ZETIA 
and statin therapy and call their healthcare professional.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.4"></a><p></p>
<h2>17.4  Breastfeeding</h2>
<p class="First">Women who are breastfeeding should be advised to not use ZETIA added to statin 
therapy. Patients who have a lipid disorder and are breastfeeding should be 
advised to discuss the options with their healthcare professionals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.5"></a><p></p>
<h2>17.5  FDA-approved Patient Labeling</h2>
<p class="First">Enter section text here</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.6"></a><p></p>
<p class="First">32147054T<br>REV 21</p>
<p>Issued July 2009<br>U.S. Patent Nos. 5,846,966; 7,030,106 and RE37,721.</p>
<p>Manufactured for:<br>Merck/Schering-Plough Pharmaceuticals<br>North Wales, PA 
19454, USA<br>By:<br>Schering Corporation<br>Kenilworth, NJ 07033, 
USA<br>or<br>Merck &amp; Co., Inc.<br>Whitehouse Station, NJ 08889, USA</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">ZETIA<span class="Sup">®</span> (ezetimibe) 
Tablets</span></p>
<p><span class="Bold">Patient Information about ZETIA (zĕt´-ē-ă)</span><br>Generic name: ezetimibe (ĕ-zĕt´-ĕ-mīb)</p>
<p>Read this information carefully before you start taking ZETIA and each time 
you get more ZETIA. There may be new information. This information does not take 
the place of talking with your doctor about your medical condition or your 
treatment. If you have any questions about ZETIA, ask your doctor. Only your 
doctor can determine if ZETIA is right for you.</p>
<p><span class="Bold">What is ZETIA?</span></p>
<p>ZETIA is a medicine used to lower levels of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and LDL (bad) 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in the blood. ZETIA is for patients who cannot control their 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels by diet and exercise alone. It can be used by itself or with 
other medicines to treat high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. You should stay on a 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering diet while taking this medicine. </p>
<p>ZETIA works to reduce the amount of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> your body absorbs. ZETIA does 
not help you lose weight. ZETIA has not been shown to prevent heart disease or 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>.</p>
<p>For more information about <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, see the "<a href="#know">What should 
I know about high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></a>?" section that follows.</p>
<p><span class="Bold">Who should not take ZETIA?</span></p>
<ul>
<li>Do not take ZETIA if you are allergic to ezetimibe, the active ingredient in 
ZETIA, or to the inactive ingredients. For a list of inactive ingredients, see 
the "<a href="#inactive">Inactive ingredients</a>" section that follows.</li>
<li>If you have active liver disease, do not take ZETIA while taking 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering medicines called statins.</li>
<li>If you are pregnant or breast-feeding, do not take ZETIA while taking a 
statin.</li>
<li>If you are a woman of childbearing age, you should use an effective method 
of birth control to prevent pregnancy while using ZETIA added to statin 
therapy.</li>
</ul>
<p>ZETIA has not been studied in children under age 10.</p>
<p><span class="Bold">What should I tell my doctor before and while taking 
ZETIA?</span></p>
<p>Tell your doctor about any prescription and non-prescription medicines you 
are taking or plan to take, including natural or herbal remedies. </p>
<p>Tell your doctor about all your medical conditions including allergies. </p>
<p>Tell your doctor if you:</p>
<ul>
<li>ever had liver problems. ZETIA may not be right for you.</li>
<li>are pregnant or plan to become pregnant. Your doctor will discuss with you 
whether ZETIA is right for you.</li>
<li>are breast-feeding. We do not know if ZETIA can pass to your baby through 
your milk. Your doctor will discuss with you whether ZETIA is right for 
you.</li>
<li>experience unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</li>
</ul>
<p><span class="Bold">How should I take ZETIA?</span></p>
<ul>
<li>Take ZETIA once a day, with or without food. It may be easier to remember to 
take your dose if you do it at the same time every day, such as with breakfast, 
dinner, or at bedtime. If you also take another medicine to reduce your 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, ask your doctor if you can take them at the same time.</li>
<li>If you forget to take ZETIA, take it as soon as you remember. However, do 
not take more than one dose of ZETIA a day.</li>
<li>Continue to follow a <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering diet while taking ZETIA. Ask your 
doctor if you need diet information.</li>
<li>Keep taking ZETIA unless your doctor tells you to stop. It is important that 
you keep taking ZETIA even if you do not feel sick.</li>
</ul>
<p>See your doctor regularly to check your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> level and to check for 
side effects. Your doctor may do blood tests to check your liver before you 
start taking ZETIA with a statin and during treatment. </p>
<p><span class="Bold">What are the possible side effects of ZETIA?</span></p>
<p>In clinical studies patients reported few side effects while taking ZETIA. 
These included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pains</span>, and feeling tired.</p>
<p>Patients have experienced severe muscle problems while taking ZETIA, usually 
when ZETIA was added to a statin drug. If you experience unexplained muscle 
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> while taking ZETIA, contact your doctor 
immediately. You need to do this promptly, because on rare occasions, these 
muscle problems can be serious, with muscle breakdown resulting in kidney 
damage.</p>
<p>Additionally, the following side effects have been reported in general use: 
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (which may require treatment right away) including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> 
of the face, lips, tongue, and/or throat that may cause difficulty in breathing 
or swallowing, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>; raised red <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, sometimes with target-shaped 
lesions; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>; alterations in some laboratory blood tests; 
liver problems; <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>; <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; 
<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling sensation</span>; <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>; <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the 
gallbladder.</p>
<p>Tell your doctor if you are having these or any other medical problems while 
on ZETIA. For a complete list of side effects, ask your doctor or pharmacist. 
</p>
<p><a href="http://"></a><span class="Bold">What should I know about high 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>?</span></p>
<p><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> is a type of fat found in your blood. Your total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is 
made up of LDL and HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. </p>
<p>LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is called "bad" <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> because it can build up in the 
wall of your arteries and form plaque. Over time, plaque build-up can cause a 
narrowing of the arteries. This narrowing can slow or block blood flow to your 
heart, brain, and other organs. High LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is a major cause of heart 
disease and one of the causes for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p>HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> is called "good" <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> because it keeps the bad 
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> from building up in the arteries. </p>
<p>Triglycerides also are fats found in your blood.</p>
<p><span class="Bold">General information about ZETIA</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in 
patient information leaflets. Do not use ZETIA for a condition for which it was 
not prescribed. Do not give ZETIA to other people, even if they have the same 
condition you have. It may harm them. </p>
<p>This summarizes the most important information about ZETIA. If you would like 
more information, talk with your doctor. You can ask your pharmacist or doctor 
for information about ZETIA that is written for health professionals. </p>
<p><a href="http://"></a><span class="Bold">Inactive ingredients:</span></p>
<p>Croscarmellose sodium, lactose monohydrate, magnesium stearate, 
microcrystalline cellulose, povidone, and sodium lauryl sulfate.</p>
<p>29480885T<br>REV 21</p>
<p>Issued July 2009<br>U.S. Patent Nos. 5,846,966; 7,030,106 and RE37,721.</p>
<div class="Figure"><img alt="image of logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb18564f-663f-4da2-9dd9-700ea9bdd398&amp;name=logo.jpg"></div>
<p>Manufactured for:<br>Merck/Schering-Plough Pharmaceuticals<br>North Wales, PA 
19454, USA<br>By:<br>Schering Corporation<br>Kenilworth, NJ 07033, 
USA<br>or<br>Merck &amp; Co., Inc.<br>Whitehouse Station, NJ 08889, USA</p>
<p>COPYRIGHT © 2001, 2002, 2007, 2008, 2009 Merck/Schering-Plough 
Pharmaceuticals.<br>All rights reserved.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">Zetia<span class="Sup">®</span><br><span class="Italics">(ezetimibe) Tablets<br>10 mg</span></span></p>
<p><span class="Bold">Rx only</span></p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cb18564f-663f-4da2-9dd9-700ea9bdd398&amp;name=package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZETIA 		
					</strong><br><span class="contentTableReg">ezetimibe tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4719(NDC:66582-414)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>EZETIMIBE</strong> (EZETIMIBE) </td>
<td class="formItem">EZETIMIBE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (CAPSULE-SHAPED) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">414</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4719-0</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4719-1</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021445</td>
<td class="formItem">12/26/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">repack, relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d63c02ef-a2c3-4dd1-b61e-6cd29b5ef341</div>
<div>Set id: cb18564f-663f-4da2-9dd9-700ea9bdd398</div>
<div>Version: 2</div>
<div>Effective Time: 20091229</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
